Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

A significant association exists between receptor tyrosine kinase-like orphan receptor 2 gene variants and the OPG/RANKL ratio in human plasma.

Ermakov S, Trofimov S, Malkin I, Livshits G.

Osteoporos Int. 2012 Jul;23(7):1899-907. doi: 10.1007/s00198-011-1820-x. Epub 2011 Nov 5.

PMID:
22057548
2.

Family-based association study of ROR2 polymorphisms with an array of radiographic hand bone strength phenotypes.

Ermakov S, Malkin I, Keter M, Kobyliansky E, Livshits G.

Osteoporos Int. 2007 Dec;18(12):1683-92. Epub 2007 Jul 10.

PMID:
17619808
4.

Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major.

Pietrapertosa AC, Minenna G, Colella SM, Santeramo TM, Renni R, D'Amore M.

Panminerva Med. 2009 Mar;51(1):17-23.

6.

Evaluation of RANK/RANKL/OPG gene polymorphisms in aggressive periodontitis.

Soedarsono N, Rabello D, Kamei H, Fuma D, Ishihara Y, Suzuki M, Noguchi T, Sakaki Y, Yamaguchi A, Kojima T.

J Periodontal Res. 2006 Oct;41(5):397-404.

PMID:
16953816
7.

Single nucleotide polymorphism of RANKL and OPG genes may play a role in bone and joint injury in rheumatoid arthritis.

Xu S, Ma XX, Hu LW, Peng LP, Pan FM, Xu JH.

Clin Exp Rheumatol. 2014 Sep-Oct;32(5):697-704. Epub 2014 Jul 17.

PMID:
25068378
8.

High levels of synovial fluid osteoprotegerin (OPG) and increased serum ratio of receptor activator of nuclear factor-kappa B ligand (RANKL) to OPG correlate with disease severity in patients with primary knee osteoarthritis.

Pilichou A, Papassotiriou I, Michalakakou K, Fessatou S, Fandridis E, Papachristou G, Terpos E.

Clin Biochem. 2008 Jun;41(9):746-9. doi: 10.1016/j.clinbiochem.2008.02.011. Epub 2008 Mar 8.

PMID:
18355453
9.

Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.

Doumouchtsis K, Perrea D, Doumouchtsis S, Tziamalis M, Poulakou M, Vlachos I, Kostakis A.

Ther Apher Dial. 2009 Feb;13(1):49-55. doi: 10.1111/j.1744-9987.2009.00653.x.

PMID:
19379170
10.

Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.

Reyes-García R, Muñoz-Torres M, García DF, Mezquita-Raya P, García Salcedo JA, de Dios Luna J.

Menopause. 2010 Jan-Feb;17(1):140-4. doi: 10.1097/gme.0b013e3181ac0cc1.

PMID:
19574937
11.

Association between radiographic hand osteoarthritis and RANKL, OPG and inflammatory markers.

Pantsulaia I, Kalichman L, Kobyliansky E.

Osteoarthritis Cartilage. 2010 Nov;18(11):1448-53. doi: 10.1016/j.joca.2010.06.009. Epub 2010 Jul 13.

12.

Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.

Nabipour I, Larijani B, Vahdat K, Assadi M, Jafari SM, Ahmadi E, Movahed A, Moradhaseli F, Sanjdideh Z, Obeidi N, Amiri Z.

Menopause. 2009 Sep-Oct;16(5):950-5. doi: 10.1097/gme.0b013e3181a181b8.

PMID:
19387415
13.
14.

Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis.

Skoumal M, Kolarz G, Haberhauer G, Woloszczuk W, Hawa G, Klingler A.

Rheumatol Int. 2005 Nov;26(1):63-9. Epub 2005 May 12.

PMID:
15889303
15.

RANKL/RANK/OPG system and bone status in females with anorexia nervosa.

Ostrowska Z, Ziora K, Oświęcimska J, Swiętochowska E, Szapska B, Wołkowska-Pokrywa K, Dyduch A.

Bone. 2012 Jan;50(1):156-60. doi: 10.1016/j.bone.2011.09.054. Epub 2011 Oct 6.

PMID:
22001124
16.

Genetic polymorphism of the OPG gene associated with breast cancer.

Ney JT, Juhasz-Boess I, Gruenhage F, Graeber S, Bohle RM, Pfreundschuh M, Solomayer EF, Assmann G.

BMC Cancer. 2013 Jan 31;13:40. doi: 10.1186/1471-2407-13-40.

17.

Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.

Chiba Y, Onouchi T, Ikeda T, Adachi J, Tamura Y, Horiuchi T.

Gerontology. 2009;55(3):275-80. doi: 10.1159/000196280. Epub 2009 Jan 22.

PMID:
19158438
18.

Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women.

Zhao HY, Liu JM, Ning G, Zhao YJ, Chen Y, Sun LH, Zhang LZ, Xu MY, Chen JL.

Osteoporos Int. 2008 Feb;19(2):221-6. Epub 2007 Aug 17.

PMID:
17703270
19.

Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker?

Spelling P, Bonfá E, Caparbo VF, Pereira RM.

Scand J Rheumatol. 2008 Nov-Dec;37(6):439-44. doi: 10.1080/03009740802116224.

PMID:
18802807
20.

Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone.

Martini G, Gennari L, Merlotti D, Salvadori S, Franci MB, Campagna S, Avanzati A, De Paola V, Valleggi F, Nuti R.

Bone. 2007 Feb;40(2):457-63. Epub 2006 Sep 18.

PMID:
16979395
Items per page

Supplemental Content

Write to the Help Desk